Bio-Rad Laboratories Company Profile (NYSE:BIO)

About Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories logoBio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NYSE:BIO
  • CUSIP: 09057220
  • Web: www.bio-rad.com
Capitalization:
  • Market Cap: $6.52014 billion
  • Outstanding Shares: 29,637,000
Average Prices:
  • 50 Day Moving Avg: $228.94
  • 200 Day Moving Avg: $213.22
  • 52 Week Range: $147.68 - $242.79
P/E:
  • Trailing P/E Ratio: 427.43
  • Foreward P/E Ratio: 49.83
  • P/E Growth: 5.15
Sales & Book Value:
  • Annual Revenue: $2.08 billion
  • Price / Sales: 3.08
  • Book Value: $94.90 per share
  • Price / Book: 2.28
Profitability:
  • EBIDTA: $233.59 million
  • Net Margins: 0.73%
  • Return on Equity: 3.15%
  • Return on Assets: 2.13%
Debt:
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 4.01%
  • Quick Ratio: 2.74%
Misc:
  • Average Volume: 149,112 shs.
  • Beta: 0.91
  • Short Ratio: 4.52
 
Frequently Asked Questions for Bio-Rad Laboratories (NYSE:BIO)

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its quarterly earnings results on Thursday, February, 23rd. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of $1.03 by $1.73. The business had revenue of $571.45 million for the quarter, compared to the consensus estimate of $574.40 million. Bio-Rad Laboratories had a return on equity of 3.15% and a net margin of 0.73%. Bio-Rad Laboratories's revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the business earned $1.68 earnings per share. View Bio-Rad Laboratories' Earnings History.

Where is Bio-Rad Laboratories' stock going? Where will Bio-Rad Laboratories' stock price be in 2017?

4 equities research analysts have issued 1-year target prices for Bio-Rad Laboratories' shares. Their forecasts range from $180.00 to $275.00. On average, they expect Bio-Rad Laboratories' share price to reach $225.00 in the next twelve months. View Analyst Ratings for Bio-Rad Laboratories.

What are analysts saying about Bio-Rad Laboratories stock?

Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:

  • 1. According to Zacks Investment Research, "Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. " (8/10/2017)
  • 2. Jefferies Group LLC analysts commented, "Time to forget everything you thought you knew about BIO -- as two separate updates y'day included several "firsts" that add conviction to our bullish thesis: 1) 2020 rev & margin goals; 2) capital allocation plan opens the door for buybacks; 3) board shuffle / quality upgrade. Bottom line: the pathway to $300+ in 2-3 yrs just got a lot clearer & BIO's new shareholder-friendly behavior eliminates the rationale for a structural valuation discount, in our view." (3/14/2017)

Who are some of Bio-Rad Laboratories' key competitors?

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:

  • Norman D. Schwartz, Chairman of the Board, President, Chief Executive Officer
  • Christine A. Tsingos, Chief Financial Officer, Executive Vice President
  • John P. Goetz, Chief Operating Officer, Executive Vice President
  • Timothy Scott Ernst, Executive Vice President, General Counsel and Secretary
  • Michael Crowley, Executive Vice President, Global Commercial Operations
  • Shannon Hall, Executive Vice President, President, Life Science Group
  • John Hertia, Executive Vice President, President, Clinical Diagnostics Group
  • Giovanni Magni, Executive Vice President, Chief Strategy Officer
  • Ronald W. Hutton, Vice President, Treasurer
  • Alice N. Schwartz, Director

Who owns Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.87%), Vanguard Group Inc. (5.67%), Atlanta Capital Management Co. L L C (5.56%), Acadian Asset Management LLC (3.02%), FMR LLC (2.40%) and TimesSquare Capital Management LLC (2.10%). Company insiders that own Bio-Rad Laboratories stock include James R Stark and Michael Crowley. View Institutional Ownership Trends for Bio-Rad Laboratories.

Who sold Bio-Rad Laboratories stock? Who is selling Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Atlanta Capital Management Co. L L C, Hermes Investment Management Ltd., The Manufacturers Life Insurance Company , Northern Trust Corp, BlueCrest Capital Management Ltd, Fort Washington Investment Advisors Inc. OH, Royce & Associates LP and First Quadrant L P CA. Company insiders that have sold Bio-Rad Laboratories stock in the last year include James R Stark and Michael Crowley. View Insider Buying and Selling for Bio-Rad Laboratories.

Who bought Bio-Rad Laboratories stock? Who is buying Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Royal Bank of Canada, Wells Fargo & Company MN, Cramer Rosenthal Mcglynn LLC, Laurion Capital Management LP, Citadel Advisors LLC, Assenagon Asset Management S.A. and Janus Henderson Group PLC. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy Bio-Rad Laboratories stock?

Shares of Bio-Rad Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of Bio-Rad Laboratories stock can currently be purchased for approximately $216.28.


MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bio-Rad Laboratories (NYSE:BIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $225.00 (4.03% upside)

Analysts' Ratings History for Bio-Rad Laboratories (NYSE:BIO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Jefferies Group LLCReiterated RatingBuy$275.00LowView Rating Details
7/13/2017Wells Fargo & CompanyInitiated CoverageOutperform -> Outperform$250.00HighView Rating Details
6/28/2017Deutsche Bank AGUpgradeHold -> Buy$220.00 -> $195.00HighView Rating Details
10/12/2016CL KingInitiated CoverageBuy$180.00N/AView Rating Details
11/4/2015Leerink SwannBoost Price Target$143.00 -> $149.00N/AView Rating Details
(Data available from 8/16/2015 forward)

Earnings

Earnings History for Bio-Rad Laboratories (NYSE:BIO)
Earnings by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Earnings History by Quarter for Bio-Rad Laboratories (NYSE BIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017$0.27$0.41$477.76 million$500.05 millionViewListenView Earnings Details
2/23/2017Q416$1.03($0.70)$574.40 million$571.45 millionViewN/AView Earnings Details
11/1/2016Q316$0.51$0.62$480.60 million$508.75 millionViewN/AView Earnings Details
8/3/2016Q2$1.13$0.61$497.80 million$516.80 millionViewN/AView Earnings Details
5/5/2016Q1$0.60$0.42$463.90 million$471.20 millionViewN/AView Earnings Details
2/25/2016Q415$1.27$1.68$570.80 million$570.56 millionViewListenView Earnings Details
11/3/2015Q315$0.54$0.59$495.55 million$469.96 millionViewN/AView Earnings Details
8/6/2015Q215$0.78$0.97$494.85 million$506.10 millionViewN/AView Earnings Details
5/5/2015Q115$0.33$0.61$474.60 million$472.80 millionViewN/AView Earnings Details
2/26/2015Q414$1.18$1.34$593.41 million$598.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.86$0.39$525.40 million$530.64 millionViewN/AView Earnings Details
8/5/2014Q214$0.95$1.09$537.58 million$536.80 millionViewN/AView Earnings Details
5/6/2014Q114$0.80$0.23$515.00 million$509.30 millionViewN/AView Earnings Details
2/27/2014Q413$1.42$1.04$586.67 million$602.60 millionViewListenView Earnings Details
11/7/2013Q313$0.91($0.25)$529.02 million$505.10 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.25$1.20$532.60 million$525.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.03$0.68$506.34 million$499.70 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.33$1.65$558.68 million$573.80 millionViewN/AView Earnings Details
11/6/2012Q312$1.14$1.48$507.79 million$498.70 millionViewN/AView Earnings Details
8/7/2012$1.19$1.69ViewN/AView Earnings Details
5/1/2012$1.02$1.09ViewN/AView Earnings Details
2/23/2012$1.67$2.08ViewN/AView Earnings Details
11/1/2011$1.53$1.61ViewN/AView Earnings Details
8/2/2011$1.47$1.41ViewN/AView Earnings Details
5/3/2011$1.32$1.16ViewN/AView Earnings Details
2/24/2011$1.35$2.41ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Rad Laboratories (NYSE:BIO)
2017 EPS Consensus Estimate: $3.23
2018 EPS Consensus Estimate: $4.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.41$0.41$0.41
Q2 20171$0.81$0.81$0.81
Q3 20171$0.39$0.39$0.39
Q4 20171$1.62$1.62$1.62
Q1 20181$1.04$1.04$1.04
Q2 20181$1.33$1.33$1.33
Q3 20181$1.07$1.07$1.07
Q4 20181$1.31$1.31$1.31
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bio-Rad Laboratories (NYSE:BIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Rad Laboratories (NYSE:BIO)
Insider Ownership Percentage: 28.29%
Institutional Ownership Percentage: 63.66%
Insider Trades by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Insider Trades by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017Michael CrowleyEVPSell700$215.91$151,137.00View SEC Filing  
3/7/2017Michael CrowleyEVPSell300$196.13$58,839.00View SEC Filing  
11/9/2016James R. StarkVPSell1,299$171.42$222,674.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bio-Rad Laboratories (NYSE:BIO)
Latest Headlines for Bio-Rad Laboratories (NYSE:BIO)
Source:
DateHeadline
americanbankingnews.com logoBio-Rad Laboratories, Inc. (NYSE:BIO) EVP Michael Crowley Sells 700 Shares
www.americanbankingnews.com - August 11 at 10:36 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - August 10 at 4:32 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
finance.yahoo.com - August 10 at 2:52 AM
finance.yahoo.com logoBio-Rad Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : BIO-US : August 7, 2017
finance.yahoo.com - August 7 at 5:04 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 7 at 8:26 AM
americanbankingnews.com logoBio-Rad Laboratories, Inc. Forecasted to Post Q3 2017 Earnings of $0.39 Per Share (NYSE:BIO)
www.americanbankingnews.com - August 7 at 8:08 AM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (NYSE:BIO) Rating Lowered to C+ at TheStreet
www.americanbankingnews.com - August 5 at 9:36 AM
finance.yahoo.com logoEdited Transcript of BIO earnings conference call or presentation 3-Aug-17 9:00pm GMT
finance.yahoo.com - August 4 at 4:50 PM
finance.yahoo.com logoBio-Rad misses 2Q profit forecasts
finance.yahoo.com - August 4 at 4:50 PM
finance.yahoo.com logoBio-Rad posts 2Q profit
finance.yahoo.com - August 4 at 4:50 PM
americanbankingnews.com logoZacks: Analysts Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Post Quarterly Sales of $515.04 Million
www.americanbankingnews.com - August 4 at 9:34 AM
finance.yahoo.com logoInvestor Network: Bio-Rad Laboratories, Inc. to Host Earnings Call
finance.yahoo.com - August 3 at 6:01 PM
finance.yahoo.com logoBio-Rad Reports Second-Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 6:01 PM
finance.yahoo.com logoShould You Buy Bio-Rad Laboratories (BIO) Ahead of Earnings?
finance.yahoo.com - August 2 at 5:17 PM
reuters.com logoBio-Rad brings patent case against upstart rival 10X Genomics
www.reuters.com - August 1 at 10:48 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) to Release Earnings on Thursday
www.americanbankingnews.com - July 27 at 7:30 AM
prnewswire.com logoMultiplexed Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
www.prnewswire.com - July 21 at 11:12 PM
businesswire.com logoGlobal Microbiology & Bacterial Culture for Industrial Testing Market Analysis 2014-2025 - Innovations and Advancing Microbiology Research in Context With Media & Reagents ...
www.businesswire.com - July 21 at 11:12 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Bio-Rad Laboratories, Inc. (BIO)
www.americanbankingnews.com - July 15 at 4:14 PM
bizjournals.com logoIn Vitro Diagnostics Quality Control Market by Application, Source, Type - Global Forecast to 2022
www.bizjournals.com - July 14 at 3:42 AM
prnewswire.com logoMicrobiological Testing of Water Market is projected to reach USD 1.59 billion by 2022
www.prnewswire.com - July 14 at 3:42 AM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 13 at 8:28 AM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (NYSE:BIO) Expected to Post Quarterly Sales of $515.04 Million
www.americanbankingnews.com - July 12 at 9:14 AM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Expected to Announce Earnings of $0.55 Per Share
www.americanbankingnews.com - July 10 at 10:24 PM
finance.yahoo.com logoBio-Rad to Report Second-Quarter 2017 Financial Results Thursday, August 3, 2017
finance.yahoo.com - July 10 at 9:36 PM
marketwatch.com logoIn Vitro Diagnostics (IVD) Quality Control Market Worth 1.04 Billion USD by 2022
www.marketwatch.com - July 7 at 2:14 AM
rttnews.com logoBio-Rad Laboratories Inc. (BIO) Rose Past Resistance At The Highs
www.rttnews.com - July 6 at 4:08 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - July 5 at 5:34 PM
prnewswire.com logoBiochips (Microarrays/Microfluidics) Global Market â€" Forecast To 2023
www.prnewswire.com - June 30 at 3:45 AM
benzinga.com logoWith 'Tunnel's End' In Sight, Deutsche Upgrades Bio-Rad Labs
www.benzinga.com - June 28 at 3:18 PM
finance.yahoo.com logoAdamas Appoints New Chief Financial Officer
finance.yahoo.com - June 28 at 3:18 PM
finance.yahoo.com logoBio-Rad Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : BIO-US : June 28, 2017
finance.yahoo.com - June 28 at 3:18 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Upgraded by Deutsche Bank AG to "Buy"
www.americanbankingnews.com - June 28 at 8:19 AM
prnewswire.com logoSingle-cell Analysis Market is expected to reach USD 3.59 billion by 2022
www.prnewswire.com - June 26 at 4:31 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - June 24 at 2:26 PM
bizjournals.com logoMicrobiological Testing of Water Market Worth 1.59 Billion USD by 2022
www.bizjournals.com - June 24 at 6:07 AM
finance.yahoo.com logoBio-Rad (BIO) Scores a Strong Buy Right Now: Here's How
finance.yahoo.com - June 22 at 11:42 AM
americanbankingnews.com logoZacks: Bio-Rad Laboratories, Inc. (BIO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 21 at 6:32 PM
prnewswire.com logoGlobal Cancer Tissue Diagnostics Market to Increase at a CAGR of 8.3% Over the Forecast Period (2016-2026)
www.prnewswire.com - June 19 at 4:04 PM
finance.yahoo.com logoETFs with exposure to Bio-Rad Laboratories, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 4:04 PM
finance.yahoo.com logoBio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 4:39 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Expected to Post Quarterly Sales of $515.04 Million
www.americanbankingnews.com - June 16 at 1:32 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - June 14 at 11:32 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Announce Earnings of $0.55 Per Share
www.americanbankingnews.com - June 14 at 10:32 PM
reuters.com logoBRIEF-Bio Rad Laboratories receives FDA clearance for Bioplex 2200 syphilis total & RPR assay
www.reuters.com - June 13 at 1:04 PM
finance.yahoo.com logoBio-Rad Announces FDA Clearance of its BioPlex 2200 Syphilis Total & RPR Assay, a Novel Syphilis Testing Method
finance.yahoo.com - June 12 at 4:56 PM
americanbankingnews.com logoCritical Analysis: Bio-Rad Laboratories (BIO) vs. WaferGen Bio-systems (WGBS)
www.americanbankingnews.com - June 4 at 4:50 PM
americanbankingnews.com logoComparing InVitae Corp (NVTA) & Bio-Rad Laboratories (BIO)
www.americanbankingnews.com - June 4 at 10:16 AM
finance.yahoo.com logoImprimis Pharmaceuticals (IMMY) Looks Good: Stock Up 13%
finance.yahoo.com - June 2 at 5:19 PM
bizjournals.com logoIVD Market in BRIC is expected to reach USD 15.71 billion by 2022
www.bizjournals.com - May 31 at 9:01 PM

Social

Chart

Bio-Rad Laboratories (BIO) Chart for Wednesday, August, 16, 2017

This page was last updated on 8/16/2017 by MarketBeat.com Staff